Attending the ASH IMF Satellite Symposium, “Accelerating Toward Curing Myeloma: New Data, New Agents, and Evolving Treatment Paradigm,” on Friday afternoon reminded me once again why I enjoy attending ASH. Primarily because it gives me hope: Hope in knowing that the experts are working so hard to find the best treatment, hope in seeing the […]
The life expectancy of standard-risk myeloma patients has increased significantly in the last decade, thanks to novel therapies. Some trials that are in progress, such as the MAIA trial comparing Revilmid and dexamethasone (Rd) versus Daratumumab, Revilmid and dexamethasone (DRd) have not yet met their progression-free survival (PFS) end state and are at more than […]
It is hard to know what to expect from this year’s American Society of Hematology (ASH) meeting. The 62nd Annual Meeting & Exposition was to be held in San Diego, probably my most favorite location for this meeting. The weather is most often warm, especially compared to Rochester, MN, and the atmosphere is filled with […]
